{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-123366","form_type":"8-K","ticker":"DFTX","cik":"0001813814","company_name":"Definium Therapeutics, Inc.","filed_at":"2024-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.776458+00:00","generated_at":"2026-05-30T03:45:57.029737+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"MindMed Q3 net loss $13.7M; cash $295.3M; Phase 3 Voyage on track for Q4 2024","bullets":["Net loss $13.7M vs $17.9M a year ago; R&D expenses $17.2M (up $4.0M YoY) on MM120/MM402 programs.","Cash and equivalents $295.3M as of Sep 30, 2024; expected to fund operations into 2027.","Phase 3 Voyage study of MM120 ODT in GAD to start Q4 2024; 12-week topline data expected H1 2026.","Phase 3 Panorama (GAD) and Phase 3 Emerge (MDD) studies on track to initiate in H1 2025.","Completed Phase 1 study of MM402 (R(-)-MDMA) for Autism Spectrum Disorder in October 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-123366","json":"https://secwatch.observer/filing/0000950170-24-123366.json","markdown":"https://secwatch.observer/filing/0000950170-24-123366.md","text":"https://secwatch.observer/filing/0000950170-24-123366.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1813814/000095017024123366/0000950170-24-123366-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1813814/000095017024123366/mnmd-20241107.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T03:45:57.029737+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}